Related Experiment Video
Updated: Jan 29, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights
Jahnavi Janjirala1, Matthew Blanton1, Kenneth S Ramos2
1Center for Inflammatory and Infectious Diseases, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, United States.
Abstract:
Prostate cancer remains the most common cancer and the second leading cause of cancer-related mortality among men in the United States. Despite advances in therapy, relapses and progression of disease continue to pose major clinical challenges, underscoring the need for innovative strategies. A decade ago, we reviewed the emerging evidence linking Toll-like receptors (TLRs), a family of innate immune sensors, to prostate cancer initiation and progression. Since then, substantial advances have deepened our understanding of TLR biology in prostate cancer, revealing their role in either promoting tumor growth or activating anti-tumor immunity depending on cellular context and signaling pathways. Recent studies have expanded knowledge of TLR expression on both immune and tumor cells, identified key endogenous ligands driving chronic inflammation, and uncovered microRNA-mediated regulation of TLR signaling. Moreover, new insights into TLR polymorphisms and their potential association with cancer risk, as well as preclinical and clinical progress in TLR-targeted immunotherapies, highlight both opportunities and challenges in translating TLR biology into therapeutic applications. In this review, we update the field by summarizing the latest discoveries, evaluating the complexities of TLR signaling in prostate cancer, and discussing how this evolving knowledge may inform future biomarker development and immunotherapeutic strategies.
Insights
Toll-like receptors (TLRs) play a complex role in prostate cancer, influencing tumor growth or immunity. Understanding TLR signaling is key for developing new immunotherapies and biomarkers for this common cancer.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Prostate cancer is a leading cause of mortality in men, with disease relapse posing significant clinical challenges.
- Toll-like receptors (TLRs), innate immune sensors, have been implicated in prostate cancer initiation and progression.
- Advances in understanding TLRs reveal their dual role in cancer, promoting tumor growth or activating anti-tumor immunity.
Purpose of the Study:
- To provide an updated review of Toll-like receptor (TLR) biology in prostate cancer.
- To summarize recent discoveries regarding TLR expression, ligands, and microRNA regulation.
- To discuss the potential of TLRs in biomarker development and immunotherapeutic strategies.
Main Methods:
- Literature review and synthesis of recent research on TLRs in prostate cancer.
- Analysis of studies on TLR expression, endogenous ligands, and microRNA-mediated regulation.
- Evaluation of preclinical and clinical data on TLR-targeted immunotherapies.
Main Results:
- TLR signaling in prostate cancer is context-dependent, influencing either tumor promotion or anti-tumor immunity.
- Recent studies have elucidated TLR expression patterns on immune and tumor cells and identified key inflammatory ligands.
- MicroRNA regulation of TLR signaling and the impact of TLR polymorphisms on cancer risk have been uncovered.
Conclusions:
- TLR biology offers complex insights into prostate cancer pathogenesis.
- Further understanding of TLR signaling complexities is crucial for advancing biomarker discovery.
- TLR-targeted immunotherapies present promising avenues for future prostate cancer treatment strategies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Emerging Adulthood
Introduction Cardiac Emergencies
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Internal Receptors
Electrical Current

